Cargando…
New Antithrombotic Drugs in Acute Coronary Syndrome
In recent years, much progress has been made in the field of antithrombotic drugs in acute coronary syndrome (ACS) treatment, as reflected by the introduction of the more potent P2Y12-inhibitors prasugrel and ticagrelor, and novel forms of concomitant anticoagulation, such as fondaparinux and bivali...
Autores principales: | Zwart, Bastiaan, Parker, William A. E., Storey, Robert F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408919/ https://www.ncbi.nlm.nih.gov/pubmed/32629976 http://dx.doi.org/10.3390/jcm9072059 |
Ejemplares similares
-
New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome
por: Goto, Shinya, et al.
Publicado: (2014) -
Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome
por: George, Sudhakar, et al.
Publicado: (2019) -
Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes
por: Bonanad, Clara, et al.
Publicado: (2022) -
Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome
por: Bor, Wilbert, et al.
Publicado: (2020) -
Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome
por: Towashiraporn, Korakoth, et al.
Publicado: (2022)